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Abstract
Background: Pruritus (itch) is a frequent, burdensome and difficult-to-treat symptom in patients with cholestasis.
Fibrates are currently under investigation for the treatment of primary biliary cholangitis in patients with a
suboptimal response to ursodeoxycholic acid. Moreover, there is empirical evidence for a possible antipruritic effect.
We aim to prove this in a randomized controlled trial, including patients with cholestatic liver diseases other than
primary biliary cholangitis that are accompanied by pruritus.
Methods: A multicenter investigator-initiated, double-blind, randomized placebo-controlled trial to evaluate the
effect of bezafibrate on cholestatic pruritus in 84 adult patients with primary biliary cholangitis or primary/
secondary sclerosing cholangitis. Primary outcome is the proportion of patients with a reduction of itch intensity of
50% or more (measured on a Visual Analog Scale) after 21 days of treatment with bezafibrate 400 mg qid or
placebo. Secondary outcomes include the effect of bezafibrate on a five-dimensional itch score, liver disease-
specific quality of life, serum liver tests and autotaxin activity. Safety will be evaluated through serum parameters for
kidney function and rhabdomyolysis as well as precise recording of (serious) adverse events. We provide a
schematic overview of the study protocol and describe the methods used to recruit and randomize patients, collect
and handle data and perform statistical analyses.
Discussion: Given its favorable safety profile and anticholestatic properties, bezafibrate may become the new
first-line treatment option for treating cholestatic pruritus.
Trial registration: Netherlands Trial Register, ID: NCT02701166. Registered on 2 March 2016;
Netherlands Trial Register, ID: NTR5436. Registered on 3 August 2015.
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Pruritus, Itch
* Correspondence: a.r.bolier@amc.uva.nl
1Tytgat Institute for Liver and Intestinal Research, Department of
Gastroenterology and Hepatology, Academic Medical Center, University of
Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bolier et al. Trials  (2017) 18:230 
DOI 10.1186/s13063-017-1966-8
Background
A wide variety of cholestatic conditions are associated
with pruritus (itch), including primary biliary cholangitis
(PBC, formerly referred to as primary biliary cirrhosis
[1]) and primary sclerosing cholangitis (PSC). The prur-
itus can occur locally or be generalized and is often
reported by patients as the most burdensome symptom
of their disease. Treatment options are limited as the
pathophysiologic mechanism is largely unknown [2]. In
our experience, resistant cases report severe sleep
deprivation, depression and even suicidal ideations. In
some patients, liver transplantation turns out to be the
only option left [3].
Fibrates in cholestatic liver diseases
Ursodeoxycholic acid (UDCA) is the only FDA- and EMA-
approved therapy for PBC, improving transplantation-free
survival. UDCA-responsive patients generally have similar
life expectancy as sex- and age-matched controls [4]. Still,
about 40% of patients do not respond to UDCA. Comple-
mentary treatment strategies are thus needed. In recent
years, several case reports and pilot studies describe
improvement of serum liver function tests upon fibrate
treatment in patients with a suboptimal response to UDCA
[5–20]. Whether or not fibrates improve transplantation-
free survival in addition to UDCA remains to be proven in
a currently ongoing phase III trial in PBC patients
(www.clinicaltrials.gov: NCT01654731). Importantly,
UDCA does not show benefit for pruritus in PBC and
PSC. According to clinical observations [21], in line with
some of the abovementioned reports [14, 17, 22, 23], beza-
fibrate does potentially have antipruritic properties. Anec-
dotally, itch complaints occur or recur after stopping the
fibrates [21, 22].
Bezafibrate as a potential alternative to current guideline-
recommended antipruritic therapies
Rifampicin, the best available evidence-based treatment
for the itch of cholestasis [4, 24, 25], has the disadvan-
tage of hepatotoxicity in up to 12% [26–32] of patients
with cholestasis during prolonged treatment. Moreover,
rifampicin induces a wide variety of cytochrome P-450
(CYP) enzymes and, therefore, interacts with many
different drugs. Fibrates would thus be an attractive
alternative treatment for itch as they seem to be safe for
long-term administration and seem to provide additional
benefits to the course of the disease (at least, for PBC).
Other treatment strategies are not as effective as rifam-
picin (e.g., bile salt sequestrants, naltrexone) or are
experimental and much more invasive (e.g., nasobiliary
drainage, plasmapheresis, ultraviolet-B phototherapy,
liver transplantation) [4].
Aim of this study: to evaluate the antipruritic effect of
fibrates
The itch-relieving effect in the abovementioned studies
was not measured as a primary outcome and was thus
not systemically objectified by current quantification
methods for itch intensity such as the widely used Visual
Analog Scale (VAS) (validated in [33], discussed in [34]).
Moreover, antipruritic effects were not controlled for
while a considerable placebo effect should be taken into
account (about 30% itch reduction was seen upon
placebo treatment in one study [35]). Thus, we would
like to validate the promising effect of fibrates on itch as
a primary outcome in a double-blind, randomized
placebo-controlled study.
Proposed molecular antipruritic effect(s) of bezafibrate
As an agonist of peroxisome proliferator-activated recep-
tors (PPARs), bezafibrate has anti-inflammatory [36–38],
anticholestatic [20, 39–42] and antifibrotic [43] proper-
ties. In the current study we hope to identify its anti-
pruritic mode of action. Our group recently showed that
serum levels of lysophosphatidic acid (LPA) and serum
autotaxin (ATX) activity, the enzyme forming the bulk
of extracellular LPA, correlate with itch intensity in
patients with cholestasis [44]. Our working hypothesis is
that during cholestasis, increased serum ATX activity
causes an increase in LPA-mediated activation of itch-
specific sensory nerve endings. Importantly, successful
guideline-approved and experimental antipruritic treat-
ments (rifampicin, nasobiliary drainage and albumin
dialysis) in patients with cholestasis correlated with a de-
cline in serum ATX activity levels [45]. Thus, secondary
objectives of the current study are determination of the
effect of bezafibrate on serum ATX activity levels and/or
screening for other pruritogens.
Objectives
The primary objective is to determine the efficacy of
bezafibrate in the treatment of moderate to severe chole-
static pruritus. Secondary objectives include efficacy in
improvement of fatigue and liver disease-related quality
of life and reduction of serum parameters of cholestasis,
cholesterol, triglycerides and autotaxin activity. Safety
will be evaluated through recording of (serious) adverse
events ((S)AEs) and (suspected unexpected) adverse
reactions ((SU)SARs) as well as serum parameters for
kidney function and rhabdomyolysis. Also, the effect of
stopping treatment on all the abovementioned variables
will be assessed.
Trial design
This is a multicenter, investigator-initiated, double-blind,
randomized placebo-controlled trial.
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Methods
Methods are described according to the Standard Proto-
col Items: Recommendations for Interventional Trials
(SPIRIT) 2013 Checklist for interventional trials which is
provided in Additional file 2.
Study setting
A total of nine academic hospitals are participating in
this study, eight in the Netherlands and one in Spain
(Barcelona). A list of study sites is provided at www.cli-
nicaltrials.gov: NCT02701166.
Inclusion criteria
Patients of 18 years or older with primary biliary cholan-
gitis (PBC), primary sclerosing cholangitis (PSC) or
secondary sclerosing cholangitis (as defined in the
clinical practice guidelines of cholestasis from 2009 by
the European Association for the Study of the Liver
(EASL) [4]) can be included if they report an itch inten-
sity of at least 5 out of 10 cm on a VAS twice within the
week before inclusion with a minimum of 2 and a
maximum of 7 days between both itch scores.
Exclusion criteria
Subjects meeting any of the following criteria will be
excluded from participation:
 Primary dermatologic abnormalities associated with
pruritus
 Concomitant guideline-recommended as well as
experimental antipruritic therapy, e.g., rifampicin,
opioid-receptor antagonists (naltrexone, naloxone),
serotonin-reuptake inhibitors (sertraline), ondansetron,
phenobarbital, propofol, lidocaine, dronabinol,
butorphanol, internal or external biliary drainage,
extracorporeal albumin dialysis, ultraviolet-B
phototherapy
NB. Topical menthol-containing agents are allowed,
as well as bile salt sequestrants (colesevelam,
cholestyramin) as long as they are taken at least 4 h
before or after intake of the study medication.
Incidental use of these agents should be noted by
patients in the diary, structural use should be noted
on the Case Report Form (CRF)
 Pregnancy, women of childbearing potential not
using contraception, breastfeeding
 Cholestasis due to obstruction that requires invasive
desobstructive treatment within the time scope of
the study (5 weeks) such as endoscopic retrograde
cholangiopancreaticography (ERCP) or surgical
removal of a tumor compressing the bile duct
 Use of opiates
 Renal insufficiency (creatinine clearance <60 mL/min)
N.B. Concomitant use of UDCA is allowed
Study interventions
Placebo tablets were developed matching the licenced
Bezalip® Retard 400 mg Actavis tablets. The composition
of the placebo tablets consists mainly of lactose mono-
hydrate and excipients used were similar to the excipi-
ents of the uncoated Bezalip® Retard 400 mg Actavis
tablets. Placebo tablets were manufactured under Good
Medicinal Practice (GMP) licence.
Additional file 3 provides a flow diagram of the study
protocol. Additionally, a schematic overview according
to the SPIRIT guidelines is provided in Fig. 1. Participa-
tion requires three 30-min outpatient clinic visits during
the course of the study: at day 0 (start of treatment,
bezafibrate or placebo), days 21 (end of treatment) and
35 (follow-up 2 weeks after stop of treatment).
Criteria for withdrawal of study subjects
 Increase in serum transaminases (alanine
aminotransferase (AST), alanine aminotransferase
(ALT)) above six times the upper limit of normal or
an increase of three or more times compared to the
start of treatment
STUDY PERIOD
Enrolment Allocation Intervention Close out
TIMEPOINT (days) -7 to -2 0 1 21 35
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
Bezafibrate or placebo
ASSESSMENTS:
VAS & 5D itch scores X X X
LSDI2.0 questionnaire X X X
Serum parameters X X X
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure: schedule of enrollment, interventions and assessments.
5D five-dimensional, LDSI Liver Disease Symptom Index, VAS Visual Analog Scale
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 If serum creatinine is within the normal range at the
start of the study, an increase above 133 μmol/L is
considered a reason for withdrawal. In case serum
creatinine is increased already at start of the study
we will allow an increase of 50% of serum creatinine
concentration
Procedures to monitor adherence to treatment
Tablets remaining after the treatment phase of the inter-
vention will be used to assess adherence to treatment.
Moreover, serum cholesterol and triglyceride levels will be
tested, reflecting treatment adherence in the bezafibrate-
treated group.
Outcomes
Visual Analog Scale (VAS) itch score
The primary endpoint will be calculated from VAS
scores obtained at study visits 1 and 2 (at start and stop
of therapy), asking patients to report the maximum itch
intensity of the past 24 h. We are using VAS itch scores
as it is the most widely used method to assess itch inten-
sity [33]. The scale consists of a 10-cm horizontal line
divided into ten equal parts numbered 0 to 10. The 0 on
the left is accompanied by a smiling face and the text
“no itch at all,” the 10 on the right is accompanied by a
sad-looking face and the text “worst itch possible.”
Mostly to promote treatment fidelity, during the 21-day
treatment period, patients will be asked to keep a diary
to score their itch intensity (VAS) twice daily (after
waking up in the morning and before going to bed in
the evening) and make notes such as the use of co-medi-
cation, side effects and other information.
Five-dimensional (5D) Pruritus Scale
The 5D Pruritus Scale [46] is increasingly used in pruritus
research, probably more accurately reflecting itch com-
plaints as it evaluates multiple dimensions of itch during
the course of the past 2 weeks: in addition to itch intensity
(degree, range 1 (not present) to 5 (unbearable)), it assesses
duration (range 1 (less than 6 h a day) to 5 (all day) and dir-
ection (range 1 (itch completely resolved) to 5 (getting
worse). Disability is rated by the extent to which itch inter-
feres with sleep (range 1 (never affects sleep) to 5 (delays
falling asleep and frequently wakes me up at night) and so-
cial/leisure activities, homework/errands and professional
activities (school/work) (all range 1 (never affects this activ-
ity) to 5 (always affects this activity)). Distribution is
assessed by marking the affected skin surfaces on a ventral
and dorsal body drawing which is an adaption made to the
original version of the 5D Pruritus Scale where a list of
body parts was listed in order to check affected sites. This
way, we aim to calculate the extent of pruritic skin as a per-
centage of the whole body surface by the “rule of nine,” a
method widely used to diagnose burn wound surface [47].
Liver Disease Symptom Index (LDSI) version 2.0
The LDSI2.0 [48] is a short questionnaire used to assess
the potential effects of bezafibrate on other liver disease-
related symptoms. It contains 18 questions regarding
complaints of arthritis, pruritus, fatigue, abdominal pain,
anorexia, jaundice and psychosocial consequences of the
disease including depression and anxiety. Complaints
can be rated on a 5-point scale; total score ranges from
18 to 90, higher scores reflecting worse symptoms.
Biological specimens
Serum will be collected from each participant at three
time points: day 0, day 21 and day 35. Measurements of
serum cholestasis parameters, including bilirubin, alka-
line phosphatase (AP), gamma glutamyltransferase
(γGT), ALT, AST, as well as albumin, lactate dehydro-
genase (LDH), creatinine kinase (CK), low- and high-
density lipoprotein (LDL, HDL) and total cholesterol,
will be measured at the sites’ diagnostic laboratories.
Furthermore, sample aliquots will be collected and
stored at −80 °C until the last patient has completed the
trial. Samples will be shipped on dry ice to the principal
investigator’s laboratory.
Autotaxin (ATX) activity will be measured using an en-
zymatic endpoint assay, in which the amount of choline
produced after 60 min of incubation of the sample with
1 μM of the substrate of ATX, lysophosphatidylcholine
(LPC), is detected by fluorescence. Bile acid species will be
determined using high-performance liquid chromatog-
raphy (HPLC).
Sample size calculation
We will compare the proportion of patients from both
treatment arms who show a clinically relevant response
to treatment which is defined as a reduction in itch in-
tensity of at least 50%. Based on former placebo-
controlled trials for cholestatic itch, selecting data only
from patients with itch scores of 5 or higher at baseline
who were treated for at least 2 weeks, we estimated
that 18% of placebo-treated patients will show the
defined response [30, 35, 49–51]. Based on empiric
observations we believe that at least 50% of
bezafibrate-treated patients will respond. Thus, we
anticipate a difference in proportions between the
bezafibrate and placebo groups of 32%.
Using Fisher’s exact test with alpha set at 0.05 we need
38 patients per group for a power of 0.80 for two-sided
testing. Taking into account a 10% possible dropout we
will include 84 patients (42 per arm) in this study. This
power calculation was made after consulting a statisti-
cian and using the statistical program nQuery Advisor
version 3.0.
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Recruitment
Patients are recruited from outpatient clinics of partici-
pating academic medical centers. After informed con-
sent, based on oral and written information (see
Additional file 1) provided by study physician or nurse,
patients are enrolled at day 0 if the itch intensity is at
least 5 out of 10 on a VAS, and all other inclusion and
exclusion criteria are met. For all patients who drop out
before day 21, we will include a replacement, whereas
patients dropping out during the follow-up phase will
not be substituted (see also Additional file 3).
The first participant was enrolled in April 2016.
Recruitment is expected to be completed in 18 months,
and will be enhanced by creating awareness among
clinicians through regular presentation of the trial at
(inter)departmental meetings. Moreover, we keep close
contact with patient organizations to advertise the trial.
Randomization and blinding
After informed consent, patients will be allocated ran-
domly to either bezafibrate or placebo treatment (ratio
1:1) as per a computer-generated randomization sched-
ule with randomly varying block sizes (maximum block
size of 4) by the sites’ investigator through a web-based
module written in ALEA (https://nl.tenalea.net, copy-
right NKI AVL, Amsterdam) by the AMC Clinical
Research Unit. Stratification takes place for the VAS itch
score at day 0 (2 strata: 5 cm ≤VAS < 7.5 cm versus
7.5 cm ≤VAS ≤ 10 cm). An automated email with the
resulting randomization number will be sent to the trial
pharmacy which allocates the patient to one of the two
treatment arms and distributes the study medication
accordingly to the patients, using identical packaging for
placebo and bezafibrate tablets. This way, patients, phy-
sicians and outcome assessors stay blinded for treatment
allocation. All investigators are aware that the pharmacy
keeps the randomization list locked until all patients
have completed the study, and that a request for
unblinding can only be done in case a serious adverse
event (SAE) occurs. Investigators at all sites keep their
own subject identification log, in a secure place, and
handle all personal data according to the local regula-
tions on personal data protection.
Data collection and management
Data collection will take place using electronic Case Report
Forms (eCRFs, written by the coordinating investigator
using web-based OpenClinica software (www.openclinica.-
com)) for the three visits, with built-in range checks for
most variables. An appointed, independent monitor verifies
entry of data on a regular basis by site visits according to a
detailed monitoring plan.
From the data collection tool, data can be exported
directly to the database software (SPSS). The
coordinating investigators manage coded data by regular
backups on a secure drive. Site agreements have been
signed by coordinating and participating centers to
assure agreement about access to, and use of, trial data.
Statistical analysis plan
Statistical analyses will be performed using SPSS
(version 22 or above) according to intention-to-treat
principle: patients who dropped out before the end of
treatment because of lack of treatment efficacy will be
included in sensitivity analyses. The nature and extent of
any missing data and coding/typing errors will be ad-
dressed in a blinded fashion and dealt with accordingly
following general principles (e.g., imputation and/or the
use of specific statistical models), as will be described in
the resulting manuscript.
Statistical tests will be two-tailed. P values < 0.05 will
be considered as statistically significant. Baseline charac-
teristics of the study population in both groups will be
depicted in a table, summarizing means ± standard devi-
ations of continuous variables and frequencies and pro-
portions (%) for categorical variables. The primary
outcome measure will be depicted in a graph. Specific
statistical methods to analyze the most important
outcome measures are addressed below. Results of these
analyses (% change in each group, P values) will be
presented in a table.
Primary outcome
The effect of bezafibrate on itch will be confirmed by a
Fisher’s exact test on the difference in the proportion of
patients responding to treatment (≥50% reduction of itch
intensity in the VAS score at day 21 compared to day 0)
between the bezafibrate and the placebo groups.
Secondary outcomes
In exploratory analyses, we will test:
 The absolute effect of a 3-week treatment as well as
a 2-week follow-up on VAS and 5D Pruritus Scale
scores (day 0 versus day 21 and day 21 versus day
35) as well as the difference of these effects between
both groups (unpaired t tests)
 The effect of a 3-week treatment on daily morning
and evening VAS scores in both groups separately
(repeated measures analysis of variance (ANOVA)
days 1–21)
 The difference in time at which patients reach the
primary endpoint (50% reduction in itch intensity)
for the first time between both groups (unpaired t
test)
 The difference in morning and evening VAS scores
within patients at day 1 (irrespective of treatment
group, paired t test)
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 The difference in the effect of a 3-week treatment as
well as a 2-week follow-up on LDSI2.0 questionnaire
total and subdomain scores between both groups
(day 0 versus day 21 and day 21 versus day 35, un-
paired t test)
 The difference in the effect of a 3-week treatment as
well as a 2-week follow-up on serum ATX activity,
AST, ALT, ALP, γGT, bilirubin, albumin, creatinine,
CK, LDH, glucose, total cholesterol, HDL- and LDL-
cholesterol and triglycerides between both groups
(day 0 versus day 21 and day 21 versus day 35). De-
pending on the distribution of the data, parametric
or nonparametric tests will be chosen, i.e., unpaired
t test and Mann-Whitney U test, respectively
 The number of AEs and SAEs during and after
treatment will be listed in a table. As few AEs are
expected, no statistical analysis will be applicable to
compare between groups
Associative analyses
Univariable and, if applicable, multivariable analysis will
be performed to find out if prerandomization itch inten-
sity stratum, gender, age, Body Mass Index (BMI),
underlying liver disease, disease stage and/or use of co-
medication relate to treatment outcome.
Interim analysis
As we are not studying an intervention for life-
threatening disease, no interim analysis will be
performed to be able to keep investigators blinded until
all 84 patients have completed the study.
Discussion
The treatment of cholestatic pruritus is one of the major
challenges in the daily practice of hepatologists. This, to-
gether with the promising effect of empirical bezafibrate
treatment, was reason for the NASL Cholestatic Liver
Diseases Study Group in collaboration with the University
of Barcelona to initiate this placebo-controlled trial.
Although rifampicin is available [4], there is consider-
able resistance among clinicians (and patients) to
prescribe (or take) rifampicin due to the risk of hepato-
toxicity [26–32]. Bezafibrate would be an attractive
alternative given its favorable side-effect profile and
disease-modifying properties (in PBC). We choose to
first show the efficacy of bezafibrate in a placebo-
controlled trial before we consider continuing by show-
ing noninferiority to rifampicin which would require
many more participants. A 3-week treatment period
seemed appropriate to us, as empirical observations
found that this was long enough to perceive an antiprur-
itic effect while we consider that this period of time is
still ethically acceptable for patients receiving placebo, as
most participants have likely suffered from itch for
months or years before participation to the trial (due to,
in our experience, patients’ and/or doctors’ delay and
prior trial and error of antipruritic therapies). Because of
this relatively short treatment duration, participants are
requested not to use any rescue medication during the
course of the study other than use of topical agents (e.g.,
menthol cream) and bile sequestrants (e.g., colestyra-
min), of the use of which should be noted in the diary.
It should be noted that the manufacturer of bezafi-
brate states that it is contraindicated in patients with
liver disease. We believe, however, that with about 20
pilot studies [4–20, 22, 23] performed in patients with
PBC and PSC, having increased AP levels as an inclusion
criteria and all showing stable or decreasing liver trans-
aminase levels during long-term treatment, it is safe to
administer bezafibrate for 3 weeks in our target
population.
We choose to only include patients with an itch inten-
sity score of 5 cm or higher on a 10-cm VAS in order to
make the primary endpoint, a reduction of itch intensity
of 50% or more, clinically relevant. We believe the VAS
score is the best available but still a subjective measure,
and the cutoff point of 5 cm has been chosen somewhat
randomly. To prevent bias we cannot reveal this inclu-
sion criterion to patients. This lack of transparency may
cause some indignation, however, especially in those
who report an itch intensity score of just below 5 cm
and have persistent itch despite having tried all currently
available options. Also, patients who experienced relief
of their complaints by taking the study medication may
be reluctant to stop treatment after 21 days. For these
groups of patients we can only advise clinicians to con-
sider prescribing bezafibrate off label, pending the trial’s
results.
Given the marked placebo effect on pruritus intensity
observed in previous clinical trials, as described above,
we have made maximum effort to assure blinding of
patients, physicians and study personnel involved. The
use of web-based randomization module and subsequent
distribution of study medication by a central pharmacy
(one in The Netherlands and one in Barcelona) directly
to the patients minimizes the risks of unblinding.
Patients and their physicians may suspect the nature of
study medication administered if, after completing the
trial, bezafibrate is prescribed off label, depending on the
response to that treatment. We believe, however, this
will not affect the reliability of the data yet collected or
processes of recruitment and data collection by the
involved physician.
Although we are capturing itch intensity data using
various measures in parallel (VAS, 5D and LDSI2.0 itch
scores during the three visits as well as daily morning
and evening VAS scores from the diaries), we endeavor
to avoid the statistical multiplicity problem by having
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defined a single confirmatory primary endpoint, based
on VAS scores during the study visits. All other data will
be used in exploratory analyses only, as defined in the
protocol. For example, previous studies described
diurnal variation of itch intensity [2, 52] where most
patients reported more intense itch in the late evening
and early nighttime. By using diaries, we will also ac-
quire information on how fast a possible effect occurs.
In addition, we hope that the use of a diary stimulates
compliance and increases accuracy of co-medication
usage and reports of side effects.
Trial status
Recruitment of patients started in March 2016 and is
ongoing at the time of submission of this manuscript.
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